Search

Author/Creator Petrella, Teresa M

1. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. Issue 5 (7th May 2021)

Authors:
Tarhini, Ahmad A; Kang, Ni; Lee, Sandra J; Hodi, F Stephen; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriet M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Ter...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 5(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Issue 7 (July 2019)

Authors:
Andrews, Miles C; Berry, Donald A; Block, Matthew S; Boland, Genevieve M; Bollin, Kathryn B; Carlino, Matteo S; Carvajal, Richard D; Cohen, Jonathan; Davar, Diwakar; Delman, Keith A; Dummer, Reinhard; Farwell, Michael D; Fisher, David E; Fusi, Alberto; Glitza, Isabella C; de Gruijl, Tanja D; Gyor...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 7(2019)
Page Start:
e378
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Issue 10105 (21st October 2017)

Authors:
Schachter, Jacob; Ribas, Antoni; Long, Georgina V; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian; Petrella, Teresa M; Hamid, Omid; Zhou, Honghong; Ebbinghaus, Scot; Ibr...
Journal:
Lancet
Issue:
Volume 390:Issue 10105(2017)
Page Start:
1853
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Issue 9 (September 2019)

Authors:
Robert, Caroline; Ribas, Antoni; Schachter, Jacob; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona M; Lotem, Michal; Larkin, James M G; Lorigan, Paul; Neyns, Bart; Blank, Christian U; Petrella, Teresa M; Hamid, Omid; Su, Shu-Chih; Krepler, Clemen...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 9(2019)
Page Start:
1239
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗